Stock Fundamentals

Company Information

Company Name
Bioatla Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US09077B1044
CIK: 0001826892
CUSIP: 09077B104
Currency: USD
Full Time Employees: 41
Phone: 858 558 0708
Fiscal Year End: December
IPO Date: Dec 16, 2020
Description:

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Address:

11085 Torreyana Road, San Diego, CA, United States, 92121

Directors & Officers

Name Title Year Born
Dr. Jay M. Short Ph.D. Co-Founder, CEO & Chairman 1958
Dr. Eric L. Sievers M.D. Chief Medical Officer 1964
Mr. Christian J. Vasquez CPA CFO, CAO, Controller & Corporate Secretary 1976
Ms. Susie Melody Senior Vice President of Human Resources NA
Dr. Cathy Chang Ph.D. Senior Vice President of Research & Development NA
Dr. Gerhard Frey Ph.D. Senior Vice President of Technology Development NA
Ms. Monica Sullivan Senior Vice President of Intellectual Property & Contracts NA
Ms. Sheri Lydick Chief Commercial Officer NA
Lisa M. Pelton Accounting Manager NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 26, 2023 Sylvia Mcbrinn N/A Purchase 80.00 $116.50 $9.32K
Dec 20, 2023 Jay M Phd Short N/A Purchase 1.00K $107.00 $107.00K
Dec 19, 2023 Lawrence Steinman N/A Purchase 400.00 $102.50 $41.00K
Sep 08, 2023 Sylvia Mcbrinn N/A Purchase 40.00 $127.00 $5.08K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Millennium Management LLC 2.76M Mar 31, 2026 3.32% $0.00 261.58%
Vanguard Group Inc 1.95M Dec 31, 2025 2.34% $0.00 0.00%
Acadian Asset Management LLC 1.23M Mar 31, 2026 1.49% $0.00 0.00%
Geode Capital Management, LLC 689.18K Mar 31, 2026 0.83% $0.00 37.75%
Deutsche Bank AG 525.35K Mar 31, 2026 0.63% $0.00 0.00%
Renaissance Technologies Corp 510.51K Mar 31, 2026 0.62% $0.00 -27.81%
BlackRock Inc 480.93K Mar 31, 2026 0.58% $0.00 0.00%
Citadel Advisors Llc 435.68K Mar 31, 2026 0.53% $0.00 0.00%
UBS Group AG 375.57K Mar 31, 2026 0.45% $0.00 66.41%
Marshall Wace Asset Management Ltd 277.63K Mar 31, 2026 0.33% $0.00 -68.86%
ADAR1 Capital Management LLC 228.11K Mar 31, 2026 0.27% $0.00 24.58%
State Street Corp 151.38K Mar 31, 2026 0.18% $0.00 0.00%
Northern Trust Corp 103.49K Mar 31, 2026 0.12% $0.00 0.00%
SIMPLEX TRADING, LLC 73.90K Mar 31, 2026 0.09% $0.00 -38.62%
Stonepine Capital Management Llc 65.39K Mar 31, 2026 0.08% $0.00 0.00%
XTX Topco Ltd 56.61K Mar 31, 2026 0.07% $0.00 -6.26%
Morgan Stanley - Brokerage Accounts 55.43K Mar 31, 2026 0.07% $0.00 26.97%
Mccormack Advisors International 51.50K Mar 31, 2026 0.06% $0.00 0.00%
Kestra Advisory Services, LLC 44.25K Mar 31, 2026 0.05% $0.00 0.00%
Susquehanna International Group, LLP 39.06K Mar 31, 2026 0.05% $0.00 -52.19%

Shares Statistics

Shares Outstanding: 1.66M
Shares Float: 1.38M
% Insiders: 562.60%
% Institutions: 2,311.80%
Short % Float: 9.83%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Extended Market Index 444.84K 0.54% ▲ 73.65% Mar 31, 2026
2 Xtrackers MSCI World Swap ETF 1C 147.69K 0.18% ▼ 0.63% Dec 31, 2025
3 Extended Equity Market Fund B 97.50K 0.12% ▲ 0.00% Dec 31, 2025
4 Extended Equity Market Fund E 97.50K 0.12% ▲ 0.00% Dec 31, 2025
5 BlackRock Extended Equity Market Fund K 83.02K 0.10% ▼ 0.73% Mar 31, 2026
6 Fidelity Total Market Index 80.52K 0.10% ▲ 0.00% Mar 31, 2026
7 Fidelity Series Total Market Index 72.83K 0.09% ▲ 0.00% Mar 31, 2026
8 NT Ext Equity Mkt Index Fund - Lending 69.79K 0.08% ▲ 0.00% Mar 31, 2026
9 Spartan Extended Market Index Pool F 48.57K 0.06% ▲ 2.35% Mar 31, 2026
10 Spartan Total Market Index Pool G 33.88K 0.04% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $10.02M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $5.85M
EBITDA: $-50.09M
Book Value: $-22.48
Earnings/Share: $-41.56
Profit Margin: 0.00%
Operating Margin: -2,519.95%
ROA (TTM): -134.45%
ROE (TTM): -813.88%
Revenue (TTM): $2.00M
Revenue/Share (TTM): $1.59
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 31.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 0.37x -0.04x 3.62x N/A -0.02x
2024-12-31 3.52x 0.06x 0.73x N/A -0.01x
2023-12-31 4.11x 0.02x 0.41x N/A -0.01x
2022-12-31 9.53x 0.01x 0.20x -65.22x -0.01x
2021-12-31 12.48x 0.01x 0.17x -32,146.67x -0.01x
2020-12-31 7.46x 0.01x 0.14x -21.67x -0.04x
2019-12-31 0.17x -0.32x 7.00x -17.34x -0.66x
2018-12-31 1.38x -0.53x 2.71x -29.75x -0.55x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BCAB.US!